179 citations
,
March 2005 in “British Journal of Dermatology” This study found that 88% of women with female pattern hair loss who received oral antiandrogens saw no progression or improvement in their condition.
8 citations
,
April 2020 in “Journal of The American Academy of Dermatology” This article discusses the potential of oral bicalutamide as a promising treatment for female pattern hair loss and reports no new clinical results.
November 2023 in “PubMed” In this study using animal models, umbilical cord stem cell conditioned media combined with oral anti-androgens improved hair regeneration in androgenetic alopecia, enhancing hair follicle cycles and reducing inflammation, suggesting potential as a promising therapy.
This meta-analysis found that combination oral contraceptive pills effectively treat hirsutism but recommends adding an antiandrogen if response is inadequate after six months.
September 2022 in “Journal of The American Academy of Dermatology” In this study, the authors highlight the potential of intradermal microinjections of dutasteride as an adjunctive therapy for androgenetic alopecia, though they note that information on its effectiveness remains limited.